Analysts Conflicted on These Healthcare Names: Gossamer Bio (GOSS), Karyopharm Therapeutics (KPTI) and Tarsus Pharmaceuticals (TARS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Gossamer Bio (GOSS – Research Report), Karyopharm Therapeutics (KPTI – Research Report) and Tarsus Pharmaceuticals (TARS – Research Report).

Gossamer Bio (GOSS)

In a report released yesterday, Carter Gould from Barclays assigned a Hold rating to Gossamer Bio, with a price target of $1.50. The company’s shares closed last Tuesday at $1.25, close to its 52-week low of $0.91.

According to TipRanks.com, Gould is a 3-star analyst with an average return of 3.3% and a 52.9% success rate. Gould covers the Healthcare sector, focusing on stocks such as Reata Pharmaceuticals, Bristol-Myers Squibb, and Travere Therapeutics.

Gossamer Bio has an analyst consensus of Strong Buy, with a price target consensus of $4.63.

See today’s best-performing stocks on TipRanks >>

Karyopharm Therapeutics (KPTI)

In a report released yesterday, Peter Lawson from Barclays assigned a Buy rating to Karyopharm Therapeutics, with a price target of $8.00. The company’s shares closed last Tuesday at $1.59, close to its 52-week low of $1.44.

According to TipRanks.com, Lawson is a 3-star analyst with an average return of 1.6% and a 42.1% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Springworks Therapeutics, Iovance Biotherapeutics, and Arvinas Holding Company.

Karyopharm Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $7.67, implying a 376.4% upside from current levels. In a report issued on July 18, H.C. Wainwright also maintained a Buy rating on the stock with a $10.00 price target.

Tarsus Pharmaceuticals (TARS)

In a report released yesterday, Balaji Prasad from Barclays assigned a Buy rating to Tarsus Pharmaceuticals, with a price target of $40.00. The company’s shares closed last Tuesday at $18.04.

According to TipRanks.com, Prasad is a 3-star analyst with an average return of 2.0% and a 43.5% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Dr Reddy’s Laboratories, Amneal Pharmaceuticals, and Pacira Pharmaceuticals.

Tarsus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $46.83, implying a 126.1% upside from current levels. In a report released yesterday, LifeSci Capital also reiterated a Buy rating on the stock with a $70.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.